Profil
Charlie Qi is currently the Senior Vice President-Global Clinical Development at Transcenta Holding Ltd.
and the Head-Oncology Product Development at Roche Global Product Development Center.
Previously, he worked as the Head-Medical Sciences at Hutchison MediPharma Ltd.
from 2012 to 2017.
Aktive Positionen von Charlie Qi
Unternehmen | Position | Beginn |
---|---|---|
TRANSCENTA HOLDING LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2020 |
Roche Global Product Development Center | Corporate Officer/Principal | 01.08.2017 |
Ehemalige bekannte Positionen von Charlie Qi
Unternehmen | Position | Ende |
---|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01.08.2017 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TRANSCENTA HOLDING LIMITED | Health Technology |
Private Unternehmen | 2 |
---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
Roche Global Product Development Center |